首页 | 官方网站   微博 | 高级检索  
     

复方肿节风雾化剂联合奥美拉唑和莫沙必利治疗反流性咽喉炎40例
引用本文:张燕平,吴宁,石玉恒.复方肿节风雾化剂联合奥美拉唑和莫沙必利治疗反流性咽喉炎40例[J].中国实验方剂学杂志,2015,21(2):209-212.
作者姓名:张燕平  吴宁  石玉恒
作者单位:1. 贵阳中医学院第二附属医院,贵阳,550003
2. 贵阳医学院生物化学与分子生物学教研室,贵阳,550004
摘    要:目的:探讨复方肿节风雾化剂联合质子泵抑制剂及胃动力药物治疗反流性咽喉炎(GERL)的临床疗效。方法:将80例GERL患者随机按数字表法分为西药组和观察组各40例。两组均采用奥美拉唑镁肠溶片,20 mg/次,口服,1次/d;枸橼酸莫沙必利片,5 mg/次,口服,3次/d。西药组加用地塞米松注射液+庆大霉素雾化吸入,1次/d。观察组加用复方肿节风雾化剂雾化吸入,1次/d。两组疗程均为8周。进行治疗前后反流症状指数(RSI)量表和反流检查评分(RFS)量表评价;治疗前后24h食管p H监测。结果:经Ridit分析,观察组临床疗效优于西药组(P0.05);治疗后观察组在声嘶或发声问题、清喉、咽喉黏液增多或后鼻溢液感、饭后或仰卧时咳嗽、刺激性咳嗽、喉中有黏滞或团块状感等方面评分及RSI总分均低于西药组(P0.01);治疗后观察组声门下水肿、喉室消失、红斑/充血、声带水肿、弥漫性喉水肿、喉黏液蓄积等方面评分及RFS总分均低于西药组(P0.01);治疗后两组酸反流总次数,5 min的次数,总计p H4的百分比和De Meester评分均比治疗前下降,但组间差异无统计学意义。结论:复方肿节风雾化剂联合奥美拉唑和莫沙必利对GERL咽喉部的症状、体征的改善作用显著。

关 键 词:反流性咽喉炎  复方肿节风雾化剂  反流症状指数  反流检查评分
收稿时间:2014/9/16 0:00:00

Clinical Observation of Added Nebulizer of Fufang Zhongjiefeng Aerosol in Treating 40 Cases with Gastroesophageal Reflux Laryngitis
ZHANG Yan-ping,WU Ning and SHI Yu-heng.Clinical Observation of Added Nebulizer of Fufang Zhongjiefeng Aerosol in Treating 40 Cases with Gastroesophageal Reflux Laryngitis[J].China Journal of Experimental Traditional Medical Formulae,2015,21(2):209-212.
Authors:ZHANG Yan-ping  WU Ning and SHI Yu-heng
Affiliation:The Second Affiliated Hospital of Guiyang College of Traditional Chinese Medicine, Guiyang 550003, China;Teaching and Research Office of Biochemistry and Molecular Biology of Guiyang Medical University, Guiyang 550004, China;The Second Affiliated Hospital of Guiyang College of Traditional Chinese Medicine, Guiyang 550003, China
Abstract:Objective: To discuss the clinical effect of nebulizer of Fufang Zhongjiefeng asrosol combined with proton pump inhibitors and gastric motility-promoting drugs in treating gastroesophageal reflux laryngitis (GERL). Method: Eighty patients with GERL were randomly divided into control group (40 cases) and observation group (40 cases) by random number table. Patients in both groups took 20 mg omeprazole magnesium enteric-coated tablets orally once daily and 5 mg mosapride citrate tablets orally thrice daily. Patients in control group added dexamethasone injection and nebulizer of gentamycin injection once daily for 8 weeks. And patients in observation group added nebulizer of Fufang Zhongjiefeng asrosol once daily for 8 weeks. Before and after treatment, scores of reflux symptom index (RSI) and reflux finding score (RFS) were graded, 24-hour pH of esophagus was detected. Result: The clinical effect in observation group was superior to that in control group (P<0.05). The scores of swallowing difficulty or breathing difficulties/suffocate attack and heartburn, acid reflux, chest pain, and the total scores of RSI in observation group were less than those in control group (P<0.01). Besides, the joint hypertrophy and granuloma/granulation tissue score, and the total RSI score in observation group were less than those in control group (P<0.01). After treatment, the total times of acid reflux and number>5 min, the percentage of the total of pH<4 and DeMeester scores in both groups were decrease as compared with the results before. But there was no statistically significant difference between the groups. Conclusion: Nebulizer of Fufang Zhongjiefeng asrosol combined with proton pump inhibitors and gastric motility-promoting drugs could ameliorate the symptom and sign of gastroesophageal reflux laryngitis, and there is obvious clinical effect.
Keywords:gastroesophageal reflux laryngitis  nebulizer of Fufang Zhongjiefeng asrosol  reflux symptom index  reflux finding score
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号